Business
PharmaCielo Announces 30,000 Kg Cannabis Extract Agreement for German Market
PharmaCielo Announces 30,000 Kg Cannabis Extract Agreement for German Market Canad...
About this update from Pharmacielo Ltd.
[{"type":"text","content":"\n\n\n\nPharmaCielo Announces 30,000 Kg Cannabis Extract Agreement for German Market\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, Jan. 27, 2020\n\n\n\nPharmaCielo will sell a broad range of extracts – including both CBD- and THC-dominant profiles – to XPhyto Therapeutics Corp., for German market distribution Three-year agreement signed, covering a minimum delivery target of 30,000 kg, beginning mid-2020 GAP and ISO 9001:2015 Certifications Provide Key Quality Confirmation to Customer TORONTO, Jan. 27, 2020 /CNW/ - PharmaCielo Ltd. (\"PharmaCielo\" or the \"Company\") (TSXV: PCLO; OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced that it has entered into a three-year agreement (the \"Agreement\") with XPhyto Therapeutics Corp. (\"XPhyto\") (CSE:XPHY; FSE:4XT), whereby PharmaCielo will supply medicinal-quality cannabis extract oils and isolates, including those containing THC, to XPhyto for analysis, further processing, product development and manufacturing at its European Union Good Manufacturing Practice-certified (\"EU GMP\") facility in Biberach in the state of Baden-Württemberg, and thereafter for sale into the German market.\n\n \n \n\n \n\"PharmaCielo has a significant opportunity to export an ever-expanding range of medicinal products into the German market, including those containing THC, and we are very excited to work with XPhyto to leverage this opportunity,\" said David Attard, CEO of PharmaCielo Ltd. \"As the largest medicinal cannabis marketplace in Europe, Germany is also the most demanding in terms of product quality.  Our ability to meet market requirements for verifiable quality parameters was essential to establishing the relationship. We expect to generate meaningful revenue through this agreement over the next three years and are focused on continuing the ramp-up of our sales efforts through 2020.\"\nXPhyto is a Canadian headquartered company focused on cannabinoid-based formul...